Baseline patient demographics
| Baseline demographics | |
|---|---|
| Patients | 46 |
| Sex (male/female) | 22/24 |
| Age m(r) | 77.8 (55–95) |
| Prior anti-VEGF injections m(r) | 42 (19–67) |
| 2.0 mg ranibizumab injections m(r) | 21 (13–24) |
| Washout period in days m(r) | 33 (28–68) |
| ETDRS BCVA m(r) | 74.2 (41–92) |
| Snellen equivalent (r) | (20/100–20/16) |
| SD OCT CST μm m(r) | 347 (188–565) |
| Intraretinal fluid n(%) | 17 (37) |
| Subretinal fluid n(%) | 21 (46) |
| Sub-RPE fluid n(%) | 18 (39) |
| No intraretinal, subretinal, or Sub-RPE fluid n(%) | 8 (17) |
anti-VEGF, anti-vascular endothelial growth factor-A; CST, central subfield thickness; ETDRS BCVA, Early Treatment Diabetic Retinopathy Study best corrected visual acuity; m, mean; OCT, optical coherence tomography; r, range; sub-RPE, subretinal pigment epithelial.